MICRO-X LIMITED — Director's Dealing 2025

Oct 15, 2025

LATE APPENDIX 3Y

Adelaide, Australia, 16 October 2025: Australian hi-tech company Micro-X Ltd (ASX:MX1) ( Micro-X or the Company), a leader in cold cathode X-ray technology for health and security markets globally, advises that due to an administrative oversight, an Appendix 3Y was not given to ASX upon the issue of shares to Non-Executive Director Ms Ilona Meyer on 20 March 2025 as a result of her participation in the Entitlement Offer announced 10 February 2025.

Ms Meyer took up an entitlement of 21,082 shares in the Entitlement Offer.

Attached is the App3Y for Ms Meyer.

The details of Ms Meyer’s shareholding disclosed in the 2025 Annual Report released on 28 August 2025 are correct.

The Company has agreements in place with each Director which address the obligations of Listing Rule 3.19A and believes that the arrangements in place are adequate to ensure compliance with Listing Rule 3.19A in future.

This ASX announcement is authorised by Richard Willson, Company Secretary of Micro-X.

About Micro-X

Micro-X Limited is an ASX listed hi-tech company developing and commercialising a range of innovative products for global health and security markets, based on proprietary cold cathode, carbon nanotube (CNT) emitter technology. The electronic control emitters with this technology enables x-ray products with significant reduction in size, weight, and power requirements, enabling greater mobility and ease of use in existing x-ray markets and a range of new and unique security applications. Micro-X has a fully vertically integrated design and production facility in Adelaide, Australia. A growing technical and commercial team based in Seattle is rapidly expanding Micro-X’s US business.

Micro-X’s product portfolio spans a number of high margin, product applications in health and security. The first mobile digital radiology products are currently sold for diagnostic imaging in global healthcare, military and veterinary applications. The US Department of Homeland Security has contracted Micro-X to design a next-generation Airport security checkpoint. A miniature brain CT imager for pre-hospital stroke diagnosis in ambulances, is being developed with funding from the Australian Government’s Medical Research Future Fund. In November 2024, US Government agency ARPA-H contracted Micro-X to develop a full-body CT.

For more information visit: www.micro-x.com

Contacts

Micro-X Limited

Investor Enquiries

Kingsley Hall , Chief Executive Officer David Allen / John Granger Rebecca Puddy , Head of Corporate Communications Hawkesbury Partners Tel: +61 8 7099 3966 Tel: +61 2 9103 9494 Email: media@micro-x.com Email: dallen@hawkesburypartners.com jgranger@hawkesburypartners.com

Micro-X Ltd. ABN 21 153 273 735, 1284 South Road, MAB Gate 2, Tonsley, South Australia 5042 www.micro-x.com

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Micro-X Limited ABN 21 153 273 735

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ilona Meyer
Date of last notice	8 May 2025

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.
Date of change	20 March 2025
No. of securities held prior to change	567,961 Fully Paid Ordinary Shares 127,877 Unlisted Performance Rights 52,631 Unlisted Options
Class	Ordinary Shares
Number acquired	21,082 Ordinary Shares
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$0.07

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after change	589,043 Fully Paid Ordinary Shares 127,877 Unlisted Performance Rights 52,631 Unlisted Options
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in the Entitlement Offer announced 10 February 2025

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change

Part 3 –[+] Closed period

Were the interests in the securities or contracts No detailed above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to proceed during this period? If prior written clearance was provided, on what date was this provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011